Pembrolizumab as a novel therapeutic option for patients with refractory thymic epithelial tumor: A case report

doi:10.12998/wjcc.v9.i5.1139

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5293)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series.

Item

Count

PDF

258

WORD

161

HTML

2574

Figures (1-5)

415

Sum=3408

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

514

Download

1361

Sum=1875

Feb 16, 2021 (publication date) through Feb 24, 2025

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Feb 16, 2021; 9(5): 1139-1147
Published online Feb 16, 2021. doi: 10.12998/wjcc.v9.i5.1139

Full Size Figure Download Figure

Figure 5 Global response: Variation of SUV of target lesions over time, from start of frontline systemic treatment to last follow-up. The corresponding treatments are noted on the graph.

Citation: Wong-Chong J, Bernadach M, Ginzac A, Veyssière H, Durando X. Pembrolizumab as a novel therapeutic option for patients with refractory thymic epithelial tumor: A case report. World J Clin Cases 2021; 9(5): 1139-1147
URL: https://www.wjgnet.com/2307-8960/full/v9/i5/1139.htm
DOI: https://dx.doi.org/10.12998/wjcc.v9.i5.1139